• Profile
Close

Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma

World Journal of Gastroenterology Aug 10, 2017

Shen J, et al. – Aim of this study is to evaluate the efficacy and safety of a new treatment modality, cellular immune therapy based on personalized peptide vaccination (PPV–DC–CTL) combined with radiotherapy, for treating advanced hepatocellular carcinoma (HCC). For patients with advanced HCC, radiotherapy combined with PPV–DC–CTL provides a new therapeutic strategy, which is well tolerated, safe, feasible and effective.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay